Advertisement
ABT vs MDT
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Medtronic (MDT) Stock Comparison
Key Takeaways
- Tickeron AI Verdict: MDT is the current favored ticker, reflecting stronger momentum, a steadier trend near its 52-week high, and fewer headline overhangs relative to ABT.
- ABT offers broad diversification across medical devices, diagnostics, nutrition, and pharmaceuticals, but recent performance has been weighed down by litigation costs and slowing growth in key product lines.
- MDT is a pure-play medical device leader that has re-accelerated organic growth and attracted a wave of analyst upgrades in recent months.
- Both companies compete directly in diabetes care and cardiovascular devices, but their market positioning and risk profiles differ meaningfully.
- For deeper coverage, explore ABT Major News and ABT Today's Price Move, along with MDT Major News and MDT Today's Price Move.
- To see how automated strategies are navigating this comparison and hundreds of others, explore Trending AI Robots.
Introduction
ABT (Abbott Laboratories) and MDT (Medtronic plc) are two of the largest and most closely followed names in healthcare, and their overlapping exposure to medical devices and diabetes technology makes them a natural pairing for a stock comparison. Investors who want diversified healthcare exposure may gravitate toward Abbott, while those seeking a focused medical technology franchise often consider Medtronic. This article examines their recent performance, business models, and risk factors to provide a balanced view of their relative performance and market positioning in the current environment.
ABT Overview and Recent Performance
Abbott Laboratories is a diversified global healthcare company spanning four segments: medical devices, diagnostics, nutrition, and established pharmaceuticals. Its medical device business, led by the FreeStyle Libre continuous glucose monitoring (CGM) franchise and a growing electrophysiology portfolio, has been a primary growth driver in recent years. In its most recent quarterly report, Abbott posted double-digit reported sales growth alongside solid comparable growth, with cancer diagnostics — supported by the Cologuard screening franchise — contributing meaningfully to the top line.
Despite these operational strengths, recent market activity has been more cautious. The company trimmed its full-year comparable sales outlook, and management pointed to slowing growth in diabetes care and electrophysiology, two areas that had previously been strong momentum engines. At the same time, Abbott announced plans to separate its nutrition business into an independent public company, a strategic move intended to sharpen focus but one that introduces near-term execution and capital-structure considerations. Reported earnings were also pressured by legal settlements tied to preterm infant formula litigation. These factors have contributed to weaker relative performance and subdued price momentum in recent months.
MDT Overview and Recent Performance
Medtronic plc is one of the world's largest pure-play medical device companies, organized across cardiovascular, neuroscience, medical-surgical, and diabetes segments. After a period of slower growth, Medtronic has shown renewed commercial momentum. Its most recent quarterly results beat revenue and adjusted earnings per share (EPS) expectations, driven by strength in cardiovascular and diabetes, and management raised its full-year organic revenue growth outlook.
Sentiment around MDT has also improved on the analyst side, with several firms lifting price targets and a few upgrading their ratings in recent months. Product catalysts, including U.S. Food and Drug Administration (FDA) clearance of the Hugo robotic-assisted surgery system for urologic procedures and the launch of the MiniMed 780G insulin delivery system, have reinforced the growth narrative. The stock has traded near the higher end of its recent range, reflecting steadier trend consistency and improving market sentiment relative to earlier periods.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each built around distinct trading styles, strategies, timeframes, performance statistics, and watchlists. With so many options available, only the most suitable bots for prevailing market conditions earn a place in the curated Trending AI Robots section. This page highlights strategies that are currently demonstrating strength, giving traders a filtered view of automated approaches rather than an overwhelming catalog. Whether you follow healthcare names like ABT and MDT or trade across broader markets, the section offers a practical starting point for evaluating data-driven strategies. Explore Trending AI Robots to review the bots currently making the cut.
Head-to-Head Comparison
From a business-model standpoint, ABT trades diversification for complexity, with nutrition, diagnostics, and established pharmaceuticals adding resilience but also exposing the company to consumer demand, reimbursement shifts, and litigation risk. MDT, by contrast, is a concentrated medical technology operator whose fortunes hinge more directly on procedure volumes and device innovation. On recent momentum, MDT has held the advantage, trading near its 52-week high with improving organic growth, while ABT has faced a guidance trim, legal costs, and slower growth in two previously fast-growing franchises. Valuation also differs: Abbott has historically commanded a premium multiple, whereas Medtronic has traded at a more modest level, though that gap has narrowed as sentiment shifted. In terms of risk, Abbott carries formula-litigation uncertainty and spin-off execution risk, while Medtronic faces the challenge of sustaining above-average growth and defending margins amid rising investment spending.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, catalyst visibility, and headline risk, Tickeron's AI currently leans toward MDT over ABT. Medtronic's steadier price trend near its 52-week high, improving organic growth, and a supportive analyst backdrop contrast with Abbott's recent guidance adjustment, litigation overhang, and decelerating growth in key segments. This assessment reflects a probabilistic reading of current conditions rather than a definitive forecast, and relative positioning could shift as new earnings, regulatory, or legal developments emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Buy and MDT is a Hold.
ABT in upward trend: 10-day moving average broke above 50-day moving average on November 02, 2026
The 10-day moving average for ABT crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on ABT as a result. In 42 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 32 of 54 cases over the following month. The odds of a continued upward trend are 59%.
ABT moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in 170 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 136 of 264 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The 10-day RSI Indicator for ABT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 16 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 53 cases where ABT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.722) is normal, around the industry mean (4.142). P/E Ratio (35.461) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.253). Dividend Yield (0.023) settles around the average of (0.011) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
MDT in -3.01% downward trend, falling for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MDT declined for three days, in 165 of 300 cases, the price declined further within the following month. The odds of a continued downward trend are 55%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MDT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 14 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 67 cases where MDT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 42%.
MDT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on MDT as a result. In 44 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
The Moving Average Convergence Divergence (MACD) for MDT just turned positive on October 12, 2026. Looking at past instances where MDT's MACD turned positive, the stock continued to rise in 23 of 42 cases over the following month. The odds of a continued upward trend are 55%.
MDT moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MDT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 47%.
Following a +3.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDT advanced for three days, in 171 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
The Aroon Indicator entered an Uptrend today. In 87 of 237 cases where MDT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 37%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. MDT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 49 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.592) is normal, around the industry mean (4.142). P/E Ratio (24.890) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (11.253). Dividend Yield (0.028) settles around the average of (0.011) among similar stocks. P/S Ratio (3.176) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ABT | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 92 | 100 | |
SMR RATING 1..100 | 68 | 68 | |
PRICE GROWTH RATING 1..100 | 43 | 12 | |
P/E GROWTH RATING 1..100 | 4 | 49 | |
SEASONALITY SCORE 1..100 | 24 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (65) in the Medical Specialties industry is in the same range as ABT (78). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
ABT's Profit vs Risk Rating (92) in the Medical Specialties industry is in the same range as MDT (100). This means that ABT’s stock grew similarly to MDT’s over the last 12 months.
ABT's SMR Rating (68) in the Medical Specialties industry is in the same range as MDT (68). This means that ABT’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (12) in the Medical Specialties industry is in the same range as ABT (43). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
ABT's P/E Growth Rating (4) in the Medical Specialties industry is somewhat better than the same rating for MDT (49). This means that ABT’s stock grew somewhat faster than MDT’s over the last 12 months.
| ABT | MDT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 52% | 2 days ago 54% |
| Stochastic ODDS (%) | 2 days ago 53% | 2 days ago 42% |
| Momentum ODDS (%) | 2 days ago 51% | 2 days ago 52% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 55% |
| TrendWeek ODDS (%) | 2 days ago 54% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 51% | 2 days ago 50% |
| Advances ODDS (%) | 10 days ago 56% | 14 days ago 54% |
| Declines ODDS (%) | 6 days ago 56% | 6 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 50% | 2 days ago 42% |
| Aroon ODDS (%) | 2 days ago 52% | 2 days ago 37% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 1 FA rating(s) are green while MDT’s FA Score has 1 green FA rating(s).
- ABT’s FA Score: 1 green, 4 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 6 TA indicator(s) are bullish while MDT’s TA Score has 6 bullish TA indicator(s).
- ABT’s TA Score: 6 bullish, 4 bearish.
- MDT’s TA Score: 6 bullish, 4 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а +0.97% price change this week, while MDT (@Medical/Nursing Services) price change was +2.74% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.76%. For the same industry, the average monthly price growth was -4.66%, and the average quarterly price growth was -1.83%.
Reported Earning Dates
ABT is expected to report earnings on Jan 27, 2027.
MDT is expected to report earnings on Nov 24, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.76% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
ABT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABT has been loosely correlated with MDT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ABT jumps, then MDT could also see price increases.
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.